Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Patient Preference × decitabine and cedazuridine drug combination × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Myeloid 1

Conditions

Myelodysplastic Syndromes 2 Leukemia, Myelomonocytic, Chronic 2 Leukemia, Myeloid, Acute 2 Patient Preference 1

Interventions

pertuzumab 1 pazopanib 1 enzalutamide 1 decitabine and cedazuridine drug combination 1 apalutamide 1 Trastuzumab 1 Surgical Procedures, Operative 1 Sunitinib 1 Radiotherapy 1 Injections, Subcutaneous 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05883956 2025-03-20

PREFER-HMA

Otsuka Australia Pharmaceutical Pty Ltd

Phase 3 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon ⚡